FIGURE 3.

The integration of AD BBM tests as a confirmatory tool to detect the presence or absence of amyloid pathology to support the determination of eligibility for DMT. The pathway follows a symptomatic patient with cognitive concerns, starting in a primary care setting (purple boxes) through secondary care (blue boxes) to determine eligibility for a DMT. Determining APOE ε4 status should occur after a confirmatory BBM test (gray outline). Patient can exit the DMT pathway at various steps when AD is not deemed the likely cause of cognitive impairment (red line). * Medical history includes history of present illness, past medical history, family history, social history, medications, allergies, and review of systems. ^† Steps 1 and 2 can occur during the same visit. ^‡ Step 3 can occur in primary or secondary care depending on how comfortable primary care HCP is interpreting and disclosing BBM and/or neuroimaging results, the availability of structural brain neuroimaging, and associated wait times. Aβ, amyloid beta; AD, Alzheimer's disease; APOE, apolipoprotein E; BBM, blood‐based biomarker; CSF, cerebrospinal fluid; DMT, disease‐modifying therapy; HCP, healthcare professional; PET, positron emission tomography; Rx, medical prescription.